GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (NAS:URGN) » Definitions » EV-to-EBITDA

URGN (UroGen Pharma) EV-to-EBITDA : -5.37 (As of Jul. 23, 2025)


View and export this data going back to 2017. Start your Free Trial

What is UroGen Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, UroGen Pharma's enterprise value is $643.33 Mil. UroGen Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-119.79 Mil. Therefore, UroGen Pharma's EV-to-EBITDA for today is -5.37.

The historical rank and industry rank for UroGen Pharma's EV-to-EBITDA or its related term are showing as below:

URGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -156.71   Med: -3.64   Max: 191.49
Current: -5.37

During the past 10 years, the highest EV-to-EBITDA of UroGen Pharma was 191.49. The lowest was -156.71. And the median was -3.64.

URGN's EV-to-EBITDA is ranked worse than
100% of 453 companies
in the Biotechnology industry
Industry Median: 10.89 vs URGN: -5.37

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-07-23), UroGen Pharma's stock price is $16.96. UroGen Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-3.180. Therefore, UroGen Pharma's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


UroGen Pharma EV-to-EBITDA Historical Data

The historical data trend for UroGen Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UroGen Pharma EV-to-EBITDA Chart

UroGen Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.40 -1.16 -2.09 -5.49 -3.05

UroGen Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.59 -5.78 -4.17 -3.05 -3.66

Competitive Comparison of UroGen Pharma's EV-to-EBITDA

For the Biotechnology subindustry, UroGen Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UroGen Pharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's EV-to-EBITDA falls into.


;
;

UroGen Pharma EV-to-EBITDA Calculation

UroGen Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=643.332/-119.787
=-5.37

UroGen Pharma's current Enterprise Value is $643.33 Mil.
UroGen Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-119.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


UroGen Pharma  (NAS:URGN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

UroGen Pharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=16.96/-3.180
=At Loss

UroGen Pharma's share price for today is $16.96.
UroGen Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.180.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


UroGen Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


UroGen Pharma Business Description

Traded in Other Exchanges
Address
400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Executives
Mark Schoenberg officer: Chief Medical Officer C/O UROGEN PHARMA LTD., 9 HA TA ASIYA STREET, RA ANANA L3 4365007
Jason Drew Smith officer: General Counsel C/O UROGEN PHARMA LTD., 400 ALEXANDER PARK DRIVE, PRINCETON NJ 08540
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
Daniel George Wildman director 12520 SUNNYDALE DRIVE, WELLINGTON FL 33414
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Dong Kim officer: Chief Financial Officer C/O UROGEN PHARMA, LTD., 400 ALEXANDER PARK DRIVE, 4TH FLOOR, PRINCETON NJ 08540
Elizabeth A. Barrett officer: Chief Executive Officer C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Molly Henderson officer: Chief Financial Officer 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Peter P. Pfreundschuh officer: CFO C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Stephen Mullennix officer: COO C/O UROGEN PHARMA LTD, 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Stuart Holden director C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Cynthia M Butitta director 3165 PORTER DRIVE, PALO ALTO CA 94304
Ron Bentsur director, officer: Chief Executive Officer 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Fred E Cohen director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102